S'abonner

3,3',5,5'-Tetramethoxybiphenyl-4,4'diol triggers oxidative stress, metabolic changes, and apoptosis-like process by reducing the PI3K/AKT/NF-κB pathway in the NCI-H460 lung cancer cell line - 05/01/24

Doi : 10.1016/j.biopha.2023.115979 
Virginia Marcia Concato-Lopes a, , Taylon Felipe Silva a, Mariana Barbosa Detoni a, Ellen Mayara Souza Cruz a, Manoela Daiele Gonçalves b, Bruna Taciane da Silva Bortoleti a, c, Fernanda Tomiotto-Pellissier a, c, d, Amanda Cristina Machado Carloto a, Maria Beatriz Madureira a, Ana Carolina Jacob Rodrigues a, c, Jéseka Gabriela Schirmann e, Aneli M. Barbosa-Dekker e, Robert F.H. Dekker f, Ivete Conchon-Costa a, Carolina Panis g, Danielle Lazarin-Bidóia a, Milena Menegazzo Miranda-Sapla a, Mário Sérgio Mantovani h, Wander R. Pavanelli a
a Laboratory of Immunoparasitology of Neglected Diseases and Cancer, Department of Immunology, Parasitology and General Pathology, Center of Biological Sciences, State University of Londrina, PR, Brazil 
b Laboratory of Biotransformation and Phytochemical, Department of Chemistry, Center of Exact Sciences, State University of Londrina, PR, Brazil 
c Graduate Program in Biosciences and Biotechnology, Carlos Chagas Institute (ICC), Fiocruz, Curitiba, PR, Brazil 
d Department of Medical Pathology, Federal University of Paraná, Curitiba, PR, Brazil 
e Laboratory Research of Bioactive Molecules, Department of Chemistry, Center of Exact Sciences, State University of Londrina, PR, Brazil 
f Federal Technological University of Paraná, Graduate Program in Environmental Engineering, Campus Londrina, Londrina, PR, Brazil 
g Laboratory of Tumor Biology, State University of West Paraná, Unioeste, Francisco Beltrao, Brazil 
h Laboratory of Toxicological Genetics, Department of General Biology, Center of Biological Sciences, State University of Londrina, PR, Brazil 

Correspondence to: Department of Immunology, Parasitology and General Pathology, Laboratory of Immunopathology of Neglected Diseases and Cancer, State University of Londrina – UEL, Rodovia Celso Garcia Cid Campus, CEP: 86057–970, Post Box 10.011 Londrina, PR, Brazil.Department of Immunology, Parasitology and General Pathology, Laboratory of Immunopathology of Neglected Diseases and Cancer, State University of Londrina – UELRodovia Celso Garcia Cid Campus, CEP: 86057–970LondrinaPRPost Box 10.011Brazil

Abstract

Lung cancer is one of the leading causes of cancer-related deaths in men and women worldwide. Current treatments have limited efficacy, cause significant side effects, and cells can develop drug resistance. New therapeutic strategies are needed to discover alternative anticancer agents with high efficacy and low-toxicity. TMBP, a biphenyl obtained by laccase-biotransformation of 2,6-dimethoxyphenol, possesses antitumor activity against A549 adenocarcinoma cells. Without causing damage to sheep erythrocytes and mouse peritoneal macrophages of BALB/c mice. In addition to being classified as a good oral drug according to in-silico studies. This study evaluated the in-vitro cytotoxic effect of TMBP on lung-cancer cell-line NCI-H460 and reports mechanisms on immunomodulation and cell death. TMBP treatment (12.5–200 μM) inhibited cell proliferation at 24, 48, and 72 h. After 24-h treatment, TMBP at IC50 (154 μM) induced various morphological and ultrastructural changes in NCI-H460, reduced migration and immunofluorescence staining of N-cadherin and β-catenin, induced increased reactive oxygen species and nitric oxide with reduced superoxide radical-anion, increased superoxide dismutase activity and reduced glutathione reductase. Treatment also caused metabolic stress, reduced glucose-uptake, intracellular lactate dehydrogenase and lactate levels, mitochondrial depolarization, increased lipid droplets, and autophagic vacuoles. TMBP induced cell-cycle arrest in the G2/M phase, death by apoptosis, increased caspase-3/7, and reduced STAT-3 immunofluorescence staining. The anticancer effect was accompanied by decreasing PI3K, AKT, ARG-1, and NF-κB levels, and increasing iNOS. These results suggest its potential as a candidate for use in future lung anticancer drug design studies.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




 : 

Schematic model of the lung anticancer effect of TMBP on the NCI-H460 large cell carcinoma cell line. Caption: TMBP, 3,3',5,5'-Tetramethoxybiphenyl-4,4'-Diol; ROS, Reactive oxygen species; NO, Nitric oxide; O2.-, Superoxide anion radical; SOD, Superoxide dismutase; GSH, Reduced glutathione; Glc, Glucose; LDH, Lactate dehydrogenase; LD, Lipid droplets; LD, Lipid droplets; AV, Autophagic vacuoles; iNOS, Induzivel nitric oxide synthase; ARG-1, Arginase-1; PI3K, phosphatidylinositol-3-kinase; AKT, Protein kinase B, pAKT, Phosphoprotein kinase B; NF-κB, Nuclear factor kappa B; STAT-3, signal transducer and activator of transcription 3; ONOO-, Peroxynitrite anion;


Schematic model of the lung anticancer effect of TMBP on the NCI-H460 large cell carcinoma cell line. Caption: TMBP, 3,3',5,5'-Tetramethoxybiphenyl-4,4'-Diol; ROS, Reactive oxygen species; NO, Nitric oxide; O2.-, Superoxide anion radical; SOD, Superoxide dismutase; GSH, Reduced glutathione; Glc, Glucose; LDH, Lactate dehydrogenase; LD, Lipid droplets; LD, Lipid droplets; AV, Autophagic vacuoles; iNOS, Induzivel nitric oxide synthase; ARG-1, Arginase-1; PI3K, phosphatidylinositol-3-kinase; AKT, Protein kinase B, pAKT, Phosphoprotein kinase B; NF-κB, Nuclear factor kappa B; STAT-3, signal transducer and activator of transcription 3; ONOO-, Peroxynitrite anion;ga1

Le texte complet de cet article est disponible en PDF.

Highlights

TMBP treatment reduces cell viability and alters morphology in NCI-H460.
The treatment reduces migratory capacity and N-cadherin and β-catenin proteins.
TMBP treatment promotes oxidative and metabolic stress on lung cancer cell-line.
TMBP induces the G2/M arrest phase, cell death, and reduces STAT-3 in NCI-H460.
The treatment act in NCI-H460 decreases PI3K/AKT/ARG-1/NF-κB and increases iNOS.

Le texte complet de cet article est disponible en PDF.

Abbreviations : LC, NSCLC, SCLC, TMBP, 2,6-DMP, ROS, DMSO, SEM, TEM, H2DCFDA, MTT, PBS, SBF, Glc, TMRE, H2O2, CCCP, NAC, NO, L-NAME, O2-, SOD, GSH, LDH, Δψm, LD, NR, MDC, CPT, ELISA, iNOS, ARG-1, PI3K, AKT, pAKT, NF-κB, pNF-κB, Nrf2, KOH, Z-DEVD-AMC substrate, Ac-DEVD-CHO inhibitor, RIPA, EDTA, TME, STAT-3, EMT, OH•-, OXPHOS, CAT, PRDXs, GPXs, ONOO-, RNS

Keywords : Treatment, Cancer, Cell Death, Redox Disruption


Plan


© 2023  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 170

Article 115979- janvier 2024 Retour au numéro
Article précédent Article précédent
  • New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model
  • Karine Rodríguez-Fernández, Gledys Reynaldo-Fernández, Stephanie Reyes-González, Camila de las Barreras, Leyanis Rodríguez-Vera, Cornelis Vlaar, Jean-Christophe M. Monbaliu, Torsten Stelzer, Jorge Duconge, Victor Mangas-Sanjuan
| Article suivant Article suivant
  • The inhibitory effects of epigallocatechin-3-gallate on calcium oxalate monohydrate crystal growth, aggregation and crystal-cell adhesion
  • Rattiyaporn Kanlaya, Rasiyakapat Kuljiratansiri, Paleerath Peerapen, Visith Thongboonkerd

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.